VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advan
VG Life Sciences, a biotechnology company, announces today an update to its Physician-IND Phase I Study to test tolerability and toxicity of its patented technology in patients with advanced stage solid tumors.